^
Association details:
Biomarker:No biomarker
Cancer:Endometrial Cancer
Drug:Jemperli (dostarlimab-gxly) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Title:

FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy

Published date:
08/01/2024
Excerpt:
On August 1, 2024, the Food and Drug Administration approved dostarlimab-gxly (Jemperli, GSK) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adult patients with primary advanced or recurrent endometrial cancer (EC).